{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:08:34Z","timestamp":1793214514235,"version":"4.5.0"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1EY028096"],"award-info":[{"award-number":["UG1EY028096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1028091"],"award-info":[{"award-number":["UG1028091"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1 EY028087"],"award-info":[{"award-number":["UG1 EY028087"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The uveitides consist of &amp;gt;30 diseases characterized by intraocular inflammation. Noninfectious intermediate, posterior, and panuveitides typically are treated with oral corticosteroids and immunosuppression, with a similar treatment approach for most diseases. Because these uveitides collectively are considered a rare disease, single-disease trials are difficult to impractical to recruit for, and most trials have included several different diseases for a given protocol treatment. However, measures of uveitis activity are disease specific, resulting in challenges for trial outcome measures. Several trials of investigational immunosuppressive drugs or biologic drugs have not demonstrated efficacy, but design problems with the outcome measures have limited the ability to interpret the results. Successful trials have included diseases for which a single uveitis activity measure suffices or a composite measure of uveitis activity is used. One potential solution to this problem is the use of a single, clinically relevant outcome, successful corticosteroid sparing, defined as inactive uveitis with a prednisone dose \u22647.5 mg\/day coupled with disease-specific guidelines for determining inactive disease. The clinical relevance of this outcome is that active uveitis is associated with increased risks of visual impairment and blindness, and that prednisone doses \u22647.5 mg\/day have a minimal risk of corticosteroid side effects. The consequence of this approach is that trial visits require a core set of measures for all participants and a disease-specific set of measures, both clinical and imaging, to assess uveitis activity. This approach is being used in the Adalimumab Versus Conventional Immunosuppression (ADVISE) Trial.<\/jats:p>","DOI":"10.1093\/epirev\/mxac001","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T20:13:18Z","timestamp":1646683998000},"page":"2-16","source":"Crossref","is-referenced-by-count":13,"title":["The Conundrum of Clinical Trials for the Uveitides: Appropriate Outcome Measures for One Treatment Used in Several Diseases"],"prefix":"10.1093","volume":"44","author":[{"given":"Douglas A","family":"Jabs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan K","family":"Berkenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M","family":"Altaweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet T","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Sugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ADVISE Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"issue":"2","key":"2024012418371692700_ref1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2013.03.027","article-title":"Approach to the diagnosis of the uveitides","volume":"156","author":"Jabs","year":"2013","journal-title":"Am J Ophthalmol."},{"issue":"3","key":"2024012418371692700_ref2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol."},{"issue":"4","key":"2024012418371692700_ref3","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/archopht.1962.00960030506014","article-title":"Epidemiology of uveitis. Incidence and prevalence in a small urban community","volume":"68","author":"Darrell","year":"1962","journal-title":"Arch Ophthalmol."},{"issue":"3","key":"2024012418371692700_ref4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in northern California; the Northern California Epidemiology of Uveitis Study","volume":"111","author":"Gritz","year":"2004","journal-title":"Ophthalmology."},{"issue":"5","key":"2024012418371692700_ref5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/09286580802478724","article-title":"Epidemiology of uveitis","volume":"15","author":"Jabs","year":"2008","journal-title":"Ophthalmic Epidemiol."},{"issue":"1","key":"2024012418371692700_ref6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9394(14)70532-X","article-title":"Causes of uveitis in the general practice of ophthalmology. UCLA Community-based Uveitis Study Group","volume":"121","author":"McCannel","year":"1996","journal-title":"Am J Ophthalmol."},{"issue":"4","key":"2024012418371692700_ref7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br J Ophthalmol."},{"issue":"9","key":"2024012418371692700_ref8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/bjo.80.9.844","article-title":"The possible impact of uveitis in blindness: a literature survey","volume":"80","author":"Suttorp-Schulten","year":"1996","journal-title":"Br J Ophthalmol."},{"issue":"5\u20136","key":"2024012418371692700_ref9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF00163549","article-title":"The natural history of uveitis","volume":"14","author":"Nussenblatt","year":"1990","journal-title":"Int Ophthalmol."},{"issue":"6","key":"2024012418371692700_ref10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.preteyeres.2011.06.005","article-title":"Understanding uveitis: the impact of research on visual outcomes","volume":"30","author":"Smet","year":"2011","journal-title":"Prog Retin Eye Res."},{"issue":"11","key":"2024012418371692700_ref11","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.ophtha.2015.07.036","article-title":"Outcome of treatment of uveitic macular\u00a0edema: the Multicenter Uveitis Steroid Treatment Trial 2-year\u00a0results","volume":"122","author":"Tomkins-Netzer","year":"2015","journal-title":"Ophthalmology."},{"issue":"2","key":"2024012418371692700_ref12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajo.2010.08.021","article-title":"Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis","volume":"151","author":"Kalinina Ayuso","year":"2011","journal-title":"Am J Ophthalmol."},{"issue":"3","key":"2024012418371692700_ref13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/09273940490883671","article-title":"Treatment of ocular inflammation","volume":"12","author":"Jabs","year":"2004","journal-title":"Ocul Immunol Inflamm."},{"issue":"4","key":"2024012418371692700_ref14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol."},{"issue":"2","key":"2024012418371692700_ref15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","article-title":"Immunosuppression for the uveitides","volume":"125","author":"Jabs","year":"2018","journal-title":"Ophthalmology."},{"issue":"6","key":"2024012418371692700_ref16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ajo.2008.04.035","article-title":"Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence","volume":"146","author":"Kempen","year":"2008","journal-title":"Am J Ophthalmol."},{"key":"2024012418371692700_ref17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2480","article-title":"Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study","volume":"339","author":"Kempen","year":"2009","journal-title":"BMJ."},{"issue":"8","key":"2024012418371692700_ref18","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.1780380815","article-title":"Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study","volume":"38","author":"Radis","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"10","key":"2024012418371692700_ref19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active non-infectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med."},{"issue":"10050","key":"2024012418371692700_ref20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet."},{"issue":"17","key":"2024012418371692700_ref21","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med."},{"issue":"3","key":"2024012418371692700_ref22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology."},{"issue":"1","key":"2024012418371692700_ref23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajo.2005.01.035","article-title":"Birdshot retinochoroidopathy: ocular complications and visual impairment","volume":"140","author":"Thorne","year":"2005","journal-title":"Am J Ophthalmol."},{"issue":"1","key":"2024012418371692700_ref24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajo.2007.08.039","article-title":"Loss of visual field among patients with birdshot chorioretinopathy","volume":"145","author":"Thorne","year":"2008","journal-title":"Am J Ophthalmol."},{"issue":"12","key":"2024012418371692700_ref25","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.ophtha.2006.05.067","article-title":"Multifocal choroiditis with panuveitis: incidence of ocular complications and of loss of visual acuity","volume":"113","author":"Thorne","year":"2006","journal-title":"Ophthalmology."},{"issue":"4","key":"2024012418371692700_ref26","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ajo.2005.04.052","article-title":"Vogt-Koyanagi-Harada disease: clinical outcomes","volume":"140","author":"Bykhovskaya","year":"2005","journal-title":"Am J Ophthalmol."},{"issue":"6","key":"2024012418371692700_ref27","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","article-title":"Beh\u00e7et disease: visual prognosis and factors influencing the development of visual loss","volume":"152","author":"Taylor","year":"2011","journal-title":"Am J Ophthalmol."},{"issue":"5","key":"2024012418371692700_ref28","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ajo.2007.01.033","article-title":"Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss","volume":"143","author":"Thorne","year":"2007","journal-title":"Am J Ophthalmol."},{"issue":"6","key":"2024012418371692700_ref29","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ajo.2008.06.019","article-title":"Ocular inflammation in Beh\u00e7et disease: incidence of ocular complications and of loss of visual acuity","volume":"146","author":"Ka\u00e7maz","year":"2008","journal-title":"Am J Ophthalmol."},{"issue":"3","key":"2024012418371692700_ref30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"2024012418371692700_ref31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"2024012418371692700_ref32","first-page":"1916","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial [published correction appears in Ophthalmology. 2012;119:212]","volume":"118","author":"Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group","year":"2011","journal-title":"Ophthalmology"},{"issue":"19","key":"2024012418371692700_ref33","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis","volume":"317","author":"The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group","year":"2017","journal-title":"J Amer Med Assoc."},{"issue":"4","key":"2024012418371692700_ref34","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol."},{"issue":"11","key":"2024012418371692700_ref35","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology."},{"issue":"3","key":"2024012418371692700_ref36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol."},{"issue":"3","key":"2024012418371692700_ref37","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"Kacmaz","year":"2010","journal-title":"Ophthalmology."},{"issue":"5","key":"2024012418371692700_ref38","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Arch Ophthalmol."},{"issue":"5","key":"2024012418371692700_ref39","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ophtha.2007.01.026","article-title":"Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis","volume":"114","author":"Hogan","year":"2007","journal-title":"Ophthalmology."},{"issue":"2","key":"2024012418371692700_ref40","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":"Cyclophosphamide for ocular inflammatory diseases","volume":"117","author":"Pujari","year":"2010","journal-title":"Ophthalmology."},{"issue":"6","key":"2024012418371692700_ref41","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.ajo.2014.08.039","article-title":"Success with single agent immunosuppression for multifocal choroidopathies","volume":"158","author":"Goldberg","year":"2014","journal-title":"Am J Ophthalmol."},{"issue":"5","key":"2024012418371692700_ref42","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch Ophthalmol."},{"issue":"9","key":"2024012418371692700_ref43","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","article-title":"Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results","volume":"126","author":"Callanan","year":"2008","journal-title":"Arch Ophthalmol."},{"issue":"4","key":"2024012418371692700_ref44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ophtha.2018.10.033","article-title":"Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic non-infectious uveitis affecting the posterior segment: twelve-month results","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology."},{"issue":"10","key":"2024012418371692700_ref45","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ophtha.2020.04.001","article-title":"Effect of a fluocinolone acetonide insert on recurrence rates in non-infectious intermediate, posterior, or panuveitis: three-year results","volume":"127","author":"Jaffe","year":"2020","journal-title":"Ophthalmology."},{"issue":"7","key":"2024012418371692700_ref46","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology."},{"issue":"6","key":"2024012418371692700_ref47","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ajo.2008.06.004","article-title":"Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis","volume":"146","author":"Kempen","year":"2008","journal-title":"Am J Ophthalmol."},{"issue":"6","key":"2024012418371692700_ref48","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3109\/09273948.2012.719258","article-title":"Optical coherence tomography evaluation in the Multicenter Uveitis Steroid Treatment (MUST) trial","volume":"20","author":"Domalpally","year":"2012","journal-title":"Ocul Immunol Inflamm."},{"issue":"9","key":"2024012418371692700_ref49","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.ophtha.2013.01.069","article-title":"Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema","volume":"120","author":"Kempen","year":"2013","journal-title":"Ophthalmology."},{"issue":"6","key":"2024012418371692700_ref50","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ajo.2011.05.028","article-title":"Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography","volume":"152","author":"Sugar","year":"2011","journal-title":"Am J Ophthalmol."},{"issue":"1","key":"2024012418371692700_ref51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archophthalmol.2009.368","article-title":"Fundus autofluorescence imaging of the white dot syndromes","volume":"128","author":"Yeh","year":"2010","journal-title":"Arch Ophthalmol."},{"issue":"7","key":"2024012418371692700_ref52","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/IAE.0b013e318286cc77","article-title":"Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging","volume":"33","author":"Spaide","year":"2013","journal-title":"Retina."},{"issue":"5","key":"2024012418371692700_ref53","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/09273948.2013.855797","article-title":"Fundus autofluorescence imaging in multifocal choroiditis: beyond the spots","volume":"22","author":"Kramer","year":"2014","journal-title":"Ocular Immunol Inflamm."},{"issue":"5","key":"2024012418371692700_ref54","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9394(99)00034-3","article-title":"The Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group","volume":"127","year":"1999","journal-title":"Am J Ophthalmol."},{"issue":"5","key":"2024012418371692700_ref55","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/jop.2010.0059","article-title":"Durezol (difluprednate ophthalmic emulsion 0.05%) compared with Pred Forte 1% in the treatment of endogenous anterior uveitis","volume":"26","author":"Foster","year":"2010","journal-title":"J Ocular Pharm Ther."},{"issue":"4","key":"2024012418371692700_ref56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/OPTH.S2452","article-title":"A new agent for the treatment of non-infectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin","volume":"2","author":"Anglade","year":"2008","journal-title":"Clin Ophthalmol."},{"key":"2024012418371692700_ref57","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2147\/OPTH.S11125","article-title":"Oral voclosporin: novel calcineurin inhibitor for treatment of non-infectious uveitis","volume":"5","author":"Roesel","year":"2011","journal-title":"Clin Ophthalmol."},{"issue":"4","key":"2024012418371692700_ref58","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of non-infectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology."},{"issue":"11","key":"2024012418371692700_ref59","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","article-title":"Intravitreal sirolimus for noninfectious uveitis: a phase III Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA)","volume":"123","author":"Nguyen","year":"2016","journal-title":"Ophthalmology."},{"issue":"10","key":"2024012418371692700_ref60","first-page":"1405","article-title":"Efficacy and safety of intravitreal sirolimus for noninfectious uveitis of the posterior segment: results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) program","volume":"127","author":"Merrill","year":"2020","journal-title":"Ophthalmol Retina."},{"issue":"3","key":"2024012418371692700_ref61","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ophtha.2018.09.044","article-title":"Efficacy and safety of sarilumab for the treatment of posterior segment non-infectious uveitis (SARIL-NIU): the phase 2 SATURN study","volume":"126","author":"Heissigerov\u00e1","year":"2019","journal-title":"Ophthalmology."},{"issue":"7","key":"2024012418371692700_ref62","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of gevokizumab in patients with Beh\u00e7et disease uveitis; an international, randomized, double-masked, placebo-controlled study and open-label extension study","volume":"26","author":"Tugal-Tutkun","year":"2018","journal-title":"Ocular Immunol Inflamm."},{"issue":"4","key":"2024012418371692700_ref63","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ajo.2009.11.019","article-title":"The Multicenter Uveitis Steroid Treatment Trial: rationale, design, and baseline characteristics","volume":"149","author":"Multicenter Uveitis Steroid Treatment Trial Research Group","year":"2010","journal-title":"Am J Ophthalmol."},{"issue":"1","key":"2024012418371692700_ref64","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuity charts for clinical research","volume":"94","author":"Ferris","year":"1982","journal-title":"Am J Ophthalmol."},{"issue":"1","key":"2024012418371692700_ref65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0161-6420(96)30742-2","article-title":"Standardizing the measurement of visual acuity for clinical research studies: guidelines from the eye care technology forum","volume":"103","author":"Ferris","year":"1996","journal-title":"Ophthalmology."},{"issue":"10","key":"2024012418371692700_ref66","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.ophtha.2007.06.047","article-title":"Visual acuity as an outcome measure in clinical trials of retinal diseases","volume":"114","author":"Beck","year":"2007","journal-title":"Ophthalmology."},{"issue":"2","key":"2024012418371692700_ref67","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreat dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology."},{"issue":"5","key":"2024012418371692700_ref68","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ophtha.2020.08.035","article-title":"Seven-year outcomes of uveitic macular edema: the multicenter uveitis steroid treatment trial and follow-up study results","volume":"128","author":"Tomkins-Netzer","year":"2021","journal-title":"Ophthalmology."},{"key":"2024012418371692700_ref69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2021.03.044","article-title":"Classification criteria for multiple sclerosis-associated intermediate uveitis","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol."},{"key":"2024012418371692700_ref70","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ajo.2021.03.045","article-title":"Classification criteria for pars planitis","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol."},{"key":"2024012418371692700_ref71","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2021.03.054","article-title":"Classification criteria for intermediate uveitis, non-pars planitis type","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol."},{"key":"2024012418371692700_ref72","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2021.03.047","article-title":"Classification criteria for sarcoidosis-associated uveitis","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol."},{"key":"2024012418371692700_ref73","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2021.03.059","article-title":"Classification criteria for birdshot chorioretinitis","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol."},{"key":"2024012418371692700_ref74","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ajo.2021.03.043","article-title":"Classification criteria for multifocal choroiditis with panuveitis","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol."},{"key":"2024012418371692700_ref75","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ajo.2021.03.046","article-title":"Classification criteria for punctate inner choroiditis","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol."},{"key":"2024012418371692700_ref76","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ajo.2021.03.038","article-title":"Classification criteria for serpiginous choroiditis","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol."},{"key":"2024012418371692700_ref77","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2021.03.058","article-title":"Classification criteria for Beh\u00e7et disease uveitis","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol."},{"key":"2024012418371692700_ref78","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ajo.2021.03.048","article-title":"Classification criteria for sympathetic ophthalmia","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol."},{"key":"2024012418371692700_ref79","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ajo.2021.03.036","article-title":"Classification criteria for Vogt-Koyanagi-Harada disease","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol."},{"issue":"10","key":"2024012418371692700_ref80","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ophtha.2008.04.026","article-title":"Comparison of antimetabolite drugs as corticosteroid-sparing therapy for non-infectious ocular inflammation","volume":"115","author":"Galor","year":"2008","journal-title":"Ophthalmology."},{"key":"2024012418371692700_ref81","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2019.07.008","article-title":"Comparison between methotrexate and mycophenolate mofetil monotherapy for the control of noninfectious ocular inflammatory diseases","volume":"208","author":"Gangaputra","year":"2019","journal-title":"Am J Ophthalmol."},{"issue":"10","key":"2024012418371692700_ref82","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jama.2019.12618","article-title":"Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial","volume":"322","author":"Rathinam","year":"2019","journal-title":"JAMA."},{"issue":"12","key":"2024012418371692700_ref83","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jamaophthalmol.2019.3964","article-title":"Antimetabolite therapy for uveitis, methotrexate or mycophenolate?","volume":"137","author":"Jabs","year":"2019","journal-title":"JAMA Ophthalmol."},{"issue":"7","key":"2024012418371692700_ref84","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jamaophthalmol.2020.1864","article-title":"Stratification clarification for methods for randomized clinical trials \u2013 reply","volume":"138","author":"Jabs","year":"2020","journal-title":"JAMA Ophthalmol."},{"issue":"7","key":"2024012418371692700_ref85","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with non-infectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology."},{"key":"2024012418371692700_ref86"}],"container-title":["Epidemiologic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/epirev\/advance-article-pdf\/doi\/10.1093\/epirev\/mxac001\/44830202\/mxac001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/epirev\/article-pdf\/44\/1\/2\/56346093\/mxac001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/epirev\/article-pdf\/44\/1\/2\/56346093\/mxac001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T18:37:57Z","timestamp":1706121477000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/epirev\/article\/44\/1\/2\/6571218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,4,20]]},"published-print":{"date-parts":[[2022,12,21]]}},"URL":"https:\/\/doi.org\/10.1093\/epirev\/mxac001","relation":{},"ISSN":["1478-6729"],"issn-type":[{"value":"1478-6729","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022]]},"published":{"date-parts":[[2022]]}}}